In Vitro and In Vivo Diagnostic Substances - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the In industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

In Vitro and In Vivo Diagnostic Substances - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - In Vitro and In Vivo Diagnostic Substances
Corporate Insider Buy Sell Ratio (Insider Count) - In Vitro and In Vivo Diagnostic Substances
In Vitro and In Vivo Diagnostic Substances - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 654.6294 -1,111
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 653.6763 -1,171
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 659.7495 -2,859
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 661.0976 -1,200
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 650.6695 -1,281
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 656.8451 -1,343
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 652.4945 -1,669
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 662.1567 -1,000
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 658.9166 -3,660
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY S - Sale D 651.4866 -1,095
2026-02-26 MYGN / Myriad Genetics, Inc. 4 Phanstiel S. Louise P - Purchase D 4.803 50,407
2026-02-26 IDXX / IDEXX Laboratories, Inc. 4 MAZELSKY JAY M - Exercise D 141.60 23,326
2026-02-26 VNRX / VolitionRx Limited 4 Batchelor Ann-Louise A - Award D 142,000
2026-02-26 VNRX / VolitionRx Limited 4 Rubin Ethel A - Award D 178,000
2026-02-26 VNRX / VolitionRx Limited 4 Innes Guy Archibald A - Award D 178,000
2026-02-26 VNRX / VolitionRx Limited 4 Plummer Nicholas A - Award D 187,000
2026-02-26 VNRX / VolitionRx Limited 4 Rootsaert Rodney Gerard A - Award D 119,000
2026-02-26 VNRX / VolitionRx Limited 4 Micallef Jacob Vincent A - Award D 149,000
2026-02-26 VNRX / VolitionRx Limited 4 Reynolds Cameron John A - Award D 486,000
2026-02-26 VNRX / VolitionRx Limited 4 Nguyen Kim A - Award D 178,000
2026-02-26 VNRX / VolitionRx Limited 4 Forterre Gael A - Award D 149,000
2026-02-26 VNRX / VolitionRx Limited 4 Hughes Terig A - Award D 202,000
2026-02-26 VNRX / VolitionRx Limited 4 Kway Jasmine A - Award D 173,000
2026-02-25 MYGN / Myriad Genetics, Inc. 4 Phanstiel S. Louise P - Purchase D 4.736 6,100
2026-02-19 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 544.08 183
2026-02-19 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 206.94 483
2026-02-19 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 141.60 719
2026-02-19 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 505.53 197
2026-02-19 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 178.26 817
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 626.2564 -1,288
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 625.2423 -204
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Vandebroek Sophie V. S - Sale D 628.646 -945
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 623.7582 -456
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 629.8625 -40
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Vandebroek Sophie V. S - Sale D 628.56 -519
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 628.2208 -2,694
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G S - Sale D 629.0906 -689
2026-02-17 NEOG / Neogen Corporation 4 Nassif Mikheal By son P - Purchase I 10.94 23
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Vandebroek Sophie V. M - Exercise D 333.90 945
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 178.26 4,180
2026-02-17 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 141.60 1,191
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Smith Martin Alexander M - Exercise D 148
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Schreck Michael M - Exercise D 1,005
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Schreck Michael M - Exercise D 367
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Johnson Michael Perkins M - Exercise D 176
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Smith Martin Alexander M - Exercise D 367
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Schreck Michael M - Exercise D 169
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Smith Martin Alexander M - Exercise D 301
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Lane Michael M - Exercise D 204
2026-02-14 IDXX / IDEXX Laboratories, Inc. 4 Erickson Michael G M - Exercise D 184
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)